

The Dietary Approaches to Stop Hypertension (DASH) Eating Pattern in Special Populations

Crystal C. Tyson · Chinazo Nwankwo · Pao-Hwa Lin ·
Laura P. Svetkey

Published online: 31 July 2012
© Springer Science+Business Media, LLC 2012

Abstract The Dietary Approaches to Stop Hypertension (DASH) trial showed that a diet rich in fruits, vegetables, low-fat dairy products with reduced total and saturated fat, cholesterol, and sugar-sweetened products effectively lowers blood pressure in individuals with prehypertension and stage I hypertension. Limited evidence is available on the safety and efficacy of the DASH eating pattern in special patient populations that were excluded from the trial. Caution should be exercised before initiating the DASH diet in patients with chronic kidney disease, chronic liver disease, and those who are prescribed renin-angiotensin-aldosterone system antagonist, but these conditions are not strict contraindications to DASH. Modifications to the DASH diet may be necessary to facilitate its use in patients with chronic heart failure, uncontrolled diabetes mellitus type II, lactose intolerance, and celiac disease. In general, the DASH diet can be adopted by most patient populations and initiated simultaneously with medication therapy and other lifestyle interventions.

Keywords Hypertension · Prehypertension · Stage I hypertension · Blood pressure · BP · Diet · Nutrition therapy · Lifestyle interventions · Medication therapy · Combination therapy · Chronic kidney disease · CKD · Diabetes mellitus · DM · Cardiovascular disease · CVD · Renin-angiotensin-aldosterone system inhibitors · RAAS inhibitors

C. C. Tyson · P.-H. Lin · L. P. Svetkey (✉)
Division of Nephrology, Department of Medicine, Duke University Medical Center,
Durham, NC 27710, USA
e-mail: laura.svetkey@duke.edu

C. C. Tyson · C. Nwankwo · P.-H. Lin · L. P. Svetkey
Sarah W. Stedman Nutrition and Metabolism Center, Duke University Medical Center,
Durham, NC 27710, USA

C. C. Tyson · C. Nwankwo · L. P. Svetkey
Duke Hypertension Center, Duke University Medical Center,
Durham, NC 27710, USA

Introduction

Approximately 30 % of US adults have hypertension [1]. It is well established that hypertension increases one's risk for coronary artery disease, stroke, and cardiovascular (CV) events [2]. Fortunately, these risks are decreased with blood pressure (BP) reduction [3]. An effective non-pharmacologic strategy to lower BP is adoption of the Dietary Approaches to Stop Hypertension (DASH) eating pattern [4]. The DASH eating pattern, which is endorsed by several national guideline committees, is recommended for management of patients with above normal BP [5–7]. Patients are unique and have different lifestyle practices and comorbid conditions. As a result, clinicians often face situations that require them to re-evaluate the appropriateness of the DASH eating pattern for these special patient populations. This article will review the original DASH trial, paying close attention to its nutritional components and study population. Our knowledge of the effectiveness and safety of the DASH eating pattern is based on several randomized trials, but is limited to participants who met inclusion criteria for those trials. Thus, we will also highlight some of the excluded patient populations and not only explore common concerns that arise regarding the appropriateness of DASH in these patients but also recommend special dietary adaptations that may help facilitate its use. Also to be addressed is the effectiveness of the DASH eating pattern with other antihypertensive therapies.

The DASH Trial

The original DASH trial was a multicenter, randomized controlled-feeding study designed to evaluate the effects of two dietary patterns on BP [4]. Aspects of the DASH eating pattern that make it both unique from other diets and effective at lowering BP are easy to highlight if one revisits the rationale for its design. BP varies across different populations, and the dietary pattern is believed to be an associated

factor. Consumption of fruits, vegetables, dairy, and reduced or no animal products (i.e., vegetarian diet) is associated with lower BP [8]. Observational studies reveal that fiber and protein intake is also associated with lower BP [9, 10]. In addition, prospective observational studies demonstrate that the intake of several minerals, such as magnesium, potassium, and calcium, has an inverse relationship with BP [11, 12]. Despite these findings, controlled studies that either isolated key components of the vegetarian diet, increased fiber, increased protein, or supplemented minerals to evaluate their individual effects on BP found only minimal benefit or conflicting results [13–15]. It was therefore hypothesized that the BP effect of these dietary interventions when provided individually may be too small to have clinical relevance and that certain nutritional components effectively lower BP when consumed in combination. The premise that a single dietary pattern that incorporates key nutrients of a vegetarian diet, increases fiber and protein intake, and provides a higher content of desired minerals could lower BP led to the design of the DASH diet. As a result, the DASH dietary pattern is rich in fruits and vegetables, low-fat dairy products, and complex carbohydrates (e.g., whole grains); it includes reduced quantities of meats, sweets, and sugar-sweetened beverages. Its nutrient profile is high in fiber, protein, magnesium, calcium, and potassium, yet low in total and saturated fats. In order to isolate the effect of these nutrients from the known BP effect of sodium restriction, the DASH dietary pattern is not a reduced sodium diet.

Investigators of the DASH trial targeted for participation individuals who would benefit from BP reduction. It is estimated that 60 % of US adults have either prehypertension or hypertension [16]. All are at increased risk for CV disease (CVD) [17, 18]. By selecting individuals ≥ 22 years of age with either prehypertension or stage 1 hypertension (SBP < 160, DBP 80–95 mmHg) for study inclusion, DASH had far-reaching implications for the majority of the US adult population. In addition, high BP disproportionately affects minorities [1]. Strategic recruitment efforts to increase diversity resulted in a study population that consisted of 60 % African-Americans and 6 % other minority groups. Therefore, DASH also had implications for a subset of the population at greatest risk for BP-related morbidity and mortality [19].

To reduce the risk of confounding because of medication adjustments during the trial, only individuals who were not taking anti-hypertensive medications were eligible to participate. Also excluded were individuals with comorbid conditions, such as uncontrolled hyperlipidemia (serum total cholesterol > 260 mg/dl or low density lipoprotein above national guidelines), poorly controlled diabetes mellitus (DM) (glycosuria or random blood glucose ≥ 180 mg/dl with a fasting blood glucose > 140 mg/dl or glycosylated hemoglobin > 8 %), grade 2 obesity with a body mass index > 35 kg/m², chronic kidney disease (CKD) [estimated

glomerular filtration rate (eGFR) < 60 ml/min/1.73 m² and serum creatinine > 1.2 mg/dl], or a CV event within the past 6 months. It was also important for the dietary intervention to be the sole source of nutrients during the study. Thus, those who were taking vitamins, mineral supplements, or antacids were asked to stop or were excluded. These exclusion criteria created knowledge gaps regarding the safety and efficacy of the DASH dietary pattern in several unrepresented patient populations.

DASH Diet in Special Patient Populations

DASH and Chronic Kidney Disease

BP control is a mainstay of treatment for patients with CKD to prevent both the progression of CKD and its associated CVD-related complications. The DASH diet, however, may not be an appropriate BP-lowering strategy for all patients with CKD because of its high content of potassium (4.5 g/day), phosphorus (1.7 g/day) and protein (1.4 g/kg/day). Metabolic complications of CKD, which can be observed as early as stage 2 (eGFR of 60 – 89 ml/min/m²), become more prevalent with disease progression [20]. Setting restrictions based on eGFR, however, is difficult because the onset of these complications is quite variable per patient, and evidence to support the timing of dietary restrictions is lacking.

The National Kidney Foundation - Kidney Disease Outcome Quality Initiative (KDOQI) guidelines do not recommend the DASH eating plan for individuals with “advanced” CKD (defined as eGFR < 60 ml/min/1.73 m²) [21]. KDOQI guidelines suggest that non-dialysis patients with advanced CKD limit protein intake to 0.6 – 0.75 g/kg/day [22]. Reasons cited for this recommendation include observational studies that show an associated reduction in the generation of nitrogenous wastes products and inorganic ions with protein restriction. Also, protein restriction was suggested to slow the progression of CKD in post-hoc analyses of the Modification of Diet in Renal Disease (MDRD) study [23]. However, because the main results of the MDRD study failed to show a benefit of protein restriction, and results from other randomized controlled trials of protein restriction in adults with CKD are inconsistent, it remains controversial whether such measures are actually warranted [24, 25].

KDOQI further recommends that potassium and phosphorus intake be restricted to 2 – 4 g/day and 0.8 – 1 g/day, respectively [21]. Hyperkalemia causes life-threatening cardiac arrhythmias, while hyperphosphatemia causes secondary hyperparathyroidism and metabolic bone disease, and is associated with an increased risk of CV events [26]. The optimal daily intake of these minerals, however, is admittedly unknown. Because the

DASH trial only enrolled participants with relatively preserved renal function (i.e., $eGFR \geq 60$ ml/min/1.73 m² (calculated by the Cockcroft-Gault equation) or a serum creatinine ≤ 1.2 mg/dl), the safety and efficacy of the DASH eating pattern for individuals with more advanced renal disease is not known. Therefore, discretion must be exercised in managing individual patients.

Despite the advisement of caution by KDOQI guidelines for patients with CKD of any degree, the DASH eating pattern for preventing or treating hypertension may be safe in patients with early stage kidney disease. It is this group of CKD patients who experience the lowest prevalence of metabolic complications and may be most likely to experience slower progression of CKD with adequate BP control [20•, 21]. Although there are no data to determine a safe cutoff, in our opinion, the DASH diet may be safely adopted by individuals with $eGFR < 60$ ml/min/1.73 m² if relevant serum electrolytes (potassium, phosphorus, calcium, magnesium) are normal and carefully monitored. Dietary recommendations in these patients should be individually tailored and guided by their individual laboratory trends. [This approach is similar to the situation in which a clinician evaluates the risks and benefits of initiating angiotensin-converting enzyme inhibitors (ACE-I) for CKD patients.] In fact, for some patients, the potassium and phosphorus content of the DASH eating pattern may actually be complementary to other medical therapies. For example, individuals who become hypokalemic after initiating non-potassium-sparing diuretics could potentially avoid the need for potassium supplementation by following the DASH diet.

On the other hand, there are many instances when the DASH eating pattern may not be appropriate for patients with CKD. This occurs for individuals who have already experienced metabolic complications or are at high risk for their development. That is, if a patient has high-normal or elevated serum potassium and phosphorus values, the DASH eating pattern should not be initiated. These patients should be advised to follow a low potassium or low phosphorus diet, and the DASH eating pattern would negate those recommendations. Caution should also be exercised for patients who are prescribed renin-angiotensin-aldosterone system (RAAS) inhibitors and/or potassium-sparing diuretics, agents known to increase serum potassium. Before initiating the DASH eating pattern in CKD patients who have been prescribed these anti-hypertensive agents, it should first be confirmed that they are normokalemic and on a stable medication regimen. Otherwise, hyperkalemia may ensue, making it difficult to determine whether the pharmacologic agent or the DASH diet was the culprit. As a result, both interventions would likely be discontinued. This would be disadvantageous for the patient who may have actually been able to tolerate and benefit from one of these interventions if used alone.

Overall, although the DASH eating pattern has not been evaluated in patients with CKD, with careful patient selection and laboratory monitoring, the benefits of successfully treating hypertension could potentially outweigh the risks of developing metabolic complications from DASH. Ultimately, additional research is needed to determine when and in whom to recommend DASH in the setting of CKD.

DASH and Chronic Heart Failure (HF)

The DASH diet may be appropriate to use for the prevention of chronic HF as well as its management. Results from prospective observational studies of adults without HF have demonstrated an association between diets consistent with the DASH eating pattern and lower rates of both incident HF in women and incident hospitalizations for or death from HF in men [27•, 28]. Reasons for this association have not been clearly elucidated. If the relationship is causal, it may be due to the lowering of BP, reduction in oxidative stress, and/or direct effects on volume status and vascular endothelium [29–32]. With regard to managing HF, clinical trial evidence is lacking on the efficacy of the DASH eating pattern for BP and symptom control. However, the content of the DASH diet is consistent with American Heart Association (AHA) recommended dietary goals to promote CV health [33]. Therefore, DASH may be appropriate for the management of this patient population.

In particular, when considering DASH in patients with HF, vitamin D intake deserves special attention. Evidence from prospective observational and cohort studies have found vitamin D deficiency to be independently associated with increased hospitalizations, reduced survival, and increased all-cause mortality in patients with HF [34–36]. Higher plasma renin activity and c-reactive protein levels in vitamin D-deficient HF patients suggest that increased RAAS activity and inflammation may play a role in their poor prognosis [34]. Double-blind, placebo-controlled studies have shown a reduction in markers of inflammation in adults after vitamin D supplementation [37]. Although observational data have demonstrated an association between vitamin D supplementation and improved outcomes for HF patients, more definitive studies are needed [35]. Nonetheless, low-fat dairy products in the DASH eating pattern serve as a good source of vitamin D.

Although, as noted above, sodium restriction is not part of the DASH dietary pattern, this micronutrient also deserves special attention when considering dietary recommendations for individuals with HF. Patients with HF are commonly instructed to restrict sodium intake. Evidence for sodium restriction is based on consensus expert opinion and limited trial data [38]. The AHA/American College of Cardiology (AHA/ACC) recommends “moderate sodium restriction” for patients with current or prior symptoms of

HF [39]. The American Dietetic Association guideline for sodium in HF patients is <2 g/day with the rationale of improving clinical symptoms (e.g., edema, fatigue) and quality of life [40]. The DASH diet plus reduced sodium intake lowers BP more than either intervention alone [41•]. However, there is no evidence to indicate whether the combination is beneficial in the setting of HF. Although AHA/ACC guidelines state that it is prudent to manage HTN “in patients with HF as if the patients did not have HF”, more research is needed to determine whether sodium restriction alone or in addition to the DASH diet effectively lowers BP in this population.

The overall nutritional value of the DASH eating pattern is also of potential benefit to patients with HF. Maintenance of adequate nutritional status is imperative as the syndrome of HF progresses. Unintentional weight loss from anorexia, early satiety, and malabsorption, which commonly occurs in advanced HF, can be disruptive to the maintenance of all nutritional plans. Hence, any nutritional plan that helps an individual achieve and maintain an adequate nutritional status, optimize CV health, and prevent co-morbidities would be beneficial as medical nutrition therapy. Though not formally tested in HF patients, adherence to the DASH diet can help accomplish such goals.

DASH and Diabetes Mellitus

The DASH eating pattern is an appropriate BP-lowering strategy for individuals with type II DM. The American Diabetic Association recommends that at-risk and diabetic patients achieve the US Department of Agriculture’s Dietary Reference Intake (DRI) for fiber, whole grains, and macronutrients. It is further recommended that these individuals limit saturated fat to <7 % total daily calories, minimize *trans* fat intake, reduce cholesterol to <200 mg/day, and limit sugar-sweetened beverages [42]. Consumption of two or more servings of fish per week is also encouraged [43]. Because the DASH diet meets these recommendations, adherence in patients with DM should be advocated.

Although individuals with uncontrolled DM were excluded from participating in the original DASH trial, it is still quite likely that the DASH eating pattern will lower BP safely in this population. The only nutrient of potential concern is carbohydrate, which makes up 55 % of total calories in the DASH diet compared to 48–51 % of the typical American diet. Concerns about the carbohydrate content of the DASH diet may be mitigated in two ways. First, in a randomized, controlled study, a low-carbohydrate version of the DASH eating pattern, which substitutes protein or monounsaturated fat for a portion of the carbohydrate content, reduced BP to a similar degree as the original DASH dietary pattern [44•]. Thus, this substitution can be recommended in patients with DM. Secondly, adoption of

the DASH diet may be facilitated by selecting foods with a low glycemic index. The glycemic index measures the degree to which carbohydrate-containing foods raise serum glucose concentration. For example, fruits with a low glycemic index, such as cherries, grapefruit, and plums, will cause less of a rise in blood glucose than higher glycemic index fruits, such as watermelon, dates, and pineapples. Results of controlled studies to investigate whether consuming low glycemic index foods aids in glucose control are conflicting and have led to discordant recommendations by expert organizations [45, 46]. Results from meta-analyses of randomized, controlled studies have shown a modest improvement in glycosylated hemoglobin, fewer hypoglycemic episodes, and a lower proportion of participants experiencing hyperglycemia [47, 48]. Although it has not been definitively determined, the strategy of selecting foods with a low glycemic index may permit patients with DM to adopt the DASH eating pattern without concern about negatively affecting blood glucose.

Overall, although evidence for a BP benefit in patients with uncontrolled DM is lacking, the overall heart healthy nutritional profile of the DASH eating pattern (low cholesterol, lean meats, fish, nuts, and whole grains) makes its use highly appropriate for BP control in this high-risk patient population. However, clinicians may choose to recommend substituting protein or mono-unsaturated fats for some of the complex carbohydrates as well as selection of foods with a low glycemic index. Additional research is needed to determine the ideal dietary pattern for both BP and glucose control.

DASH and Gastrointestinal Disorders

Chronic Liver Disease

The decision to advise a patient with chronic liver disease (CLD) to adopt the DASH eating pattern should be based on whether an individual has compensated or decompensated disease. Patients with compensated CLD are typically free to follow a well-balanced diet without restriction unless other comorbid conditions necessitate otherwise. Although not directly tested in this population, the DASH diet is likely to be safe and is therefore an appropriate strategy to lower BP. Current recommendations for nutritional therapy in patients with liver disease include small, frequent meals (to abate nausea and early satiety), daily energy intake of 35 – 40 kcal/kg, and 1.2 – 1.5 g/kg/day of protein [49]. The DASH eating plan falls well within these parameters.

Dietary intake becomes more important with disease progression. Advanced and decompensated liver disease is often accompanied by anorexia, early satiety, malabsorption, impaired protein synthesis, and hypermetabolism, all of which contribute to protein energy malnutrition (PEM)

[50]. PEM is undesirable because of its association with higher rates of ascites, gastrointestinal bleeding, infection, hepatic encephalopathy, and mortality [51]. Although the DASH diet is capable of meeting the recommended protein-energy needs of this patient population, a few other concerns exist. Common therapy with spironolactone and beta blockers, as well as an increased risk for acute kidney injury and CKD raises the concern that additional potassium from the DASH diet may cause hyperkalemia. More importantly, patients with decompensated CLD tend to have low BP, which may preclude the need for the DASH diet and any other BP-lowering strategies altogether.

Few clinicians manage patients with CLD without addressing sodium intake. However, not all CLD patients require sodium restriction. Guidelines tend to recommend restricting sodium only in individuals with cirrhosis and moderate ascites [52, 53]. Therefore, the sodium content of the DASH diet is not problematic for hypertensive patients with compensated CLD. In our opinion, sodium restriction to <2,400 mg/day, as recommended for the general population, may be considered as a separate BP-lowering strategy for these patients.

Although not evidence based, it is our opinion that the DASH diet can be safely adopted by patients with compensated disease. It is reasonable for the diet to be initiated alone or simultaneously with other BP-lowering therapies. On the other hand, the DASH diet should not be adopted by hypertensive patients with advanced, decompensated CLD. Use of medications known to increase potassium as well as the risk of acute kidney injury and CKD, with their associated complications, may cause the risk of acute complications to outweigh the benefits of BP control. Further research, however, would be helpful in this area to provide more evidence to guide management.

Diverticular Disease

In general, the diagnosis of diverticulosis and/or diverticulitis should not preclude a clinician from recommending the DASH eating plan to a new patient. Historically, patients with diverticular disease have been advised to avoid small foods, such as seeds, corn, nuts, and berries, because of concern that these foods may block or irritate diverticuli and perpetuate inflammation. However, evidence supporting this theory is lacking, and such dietary restrictions are not currently recommended. Practice guidelines of the American College of Gastroenterology does, however, recommend a diet high in fruits, vegetables, and protein, which may be preventative of disease [54]. The American Dietetic Association also recommends consumption of 20 – 35 g of fiber daily. The DASH diet meets each of these recommendations and can be adopted as a strategy to lower BP in this patient population.

Lactose Intolerance

Despite being rich in low-fat dairy products, it is possible for individuals with lactose intolerance (LI) to adopt the DASH eating pattern. The prevalence of LI varies among ethnic groups, occurring most frequently in Asians and African Americans, and least frequently in Caucasians [55]. Primary LI results from reduced genetic expression of the enzyme lactase. Lactase hydrolyzes lactose into absorbable monosaccharides. Low levels of lactase cause malabsorption of lactose-containing food products with associated nausea, flatulence, abdominal pain, and diarrhea. The severity of these symptoms depends on both the amount of lactose present in the food product and an individual's personal tolerance [56]. Individuals with primary LI will need to limit or avoid lactose-containing products for life to prevent symptoms. However, many options will allow them to follow the DASH diet.

The Dietary Guidelines for Americans 2010 recommend that individuals with lactose intolerance consume smaller portions of lactose-containing products and/or choose lactose-reduced or lactose-free versions of the offending food [57]. Consuming lactose-containing products may be facilitated further with the supplementation of oral digestive forms of lactase. Many dairy products are manufactured with lactase as an additive. Lactase can also be taken in pill form simultaneously with lactose-containing foods. Alternatively, consuming products that are completely lactose free can also be accomplished without much difficulty. This is because the food industry is laden with abundant sources of dairy-substitutes. For example, soy, rice, and almond milks serve as widely available lactose-free milk substitutes, although the effect of these substitutions on the BP-lowering effect of DASH is unknown. Nonetheless, with these modifications and substitutions, the DASH diet can be adopted for most patients with LI.

Celiac Disease

Celiac disease (CD), an autoimmune disease involving inflammation of the small intestines precipitated by ingestion of gluten in individuals with a genetic predisposition, does not preclude adoption of the DASH eating pattern. This, too, is a population for which focused research on the efficacy and safety of the DASH diet has not been conducted. However, the principle question that arises for these patients is whether the DASH eating pattern is compatible with already imposed dietary restrictions. There are two aspects of the DASH diet that require special consideration for this population. One is foods that contain gluten, a protein found in wheat and related grain species, such as barley and rye. The other is lactose-containing products.

The precipitant of intestinal inflammation in CD is gluten. Upon exposure to gluten, atrophic changes occur in villi lining the small intestines. Such damage results in malabsorption and subsequent deficiencies in multiple nutrients and fat-soluble vitamins. Although the intestines heal after gluten is eliminated from the diet, intolerance is permanent, and damage reoccurs if gluten is ever reintroduced [57, 58]. As a result, patients with CD should maintain a gluten-free diet for life. The DASH eating pattern contains seven to eight servings of grain, mostly whole grain, per day. Avoidance of prohibited grains, such as wheat, rye, and barley, is imperative for CD patients. Oat consumption should be limited to 50–60 g/day (~2 oz), and care should be taken to select from pure oat sources, which are free from cross-contamination with gluten [59]. There are many whole grain options that are compatible with both the DASH diet and dietary guidelines for CD patients. Safe whole grains include brown rice, corn, buckwheat, millet, and amaranth. Flours made from soybean, tapioca and potatoes are also safe. Being cognizant that gluten-free alternatives exist to permit dietary compliance with the DASH eating pattern will help facilitate its adoption.

Patients with CD may also acquire secondary lactose intolerance as a result of inflammatory damage incurred by the intestinal mucosa. Fortunately, inflammation abates after a period of gluten avoidance, allowing the mucosa to heal and lactase to be regenerated. Thereafter, dairy may be reintroduced in the diet. Patients with CD, who become temporarily intolerant to the DASH diet because of its dairy content, may choose lactose-reduced or lactose-free options as discussed above and/or derive calcium from other sources, such as leafy green vegetables, seeds, nuts, sardines, and fortified foods.

In general, meal planning and careful label reading will allow patients with CD to adopt the DASH eating plan. Selecting gluten-free foods and temporarily avoiding lactose if intolerance is acquired will be key.

Initiation of the DASH Eating Pattern

Most patients will require a combination of therapies to successfully achieve target BP. These strategies may include both lifestyle interventions and pharmacologic agents.

Table 1 Summary of dietary concerns of special patient populations and recommended treatment strategies

Special patient population	Conflicts with DASH diet	Treatment strategies
Chronic kidney disease	High potassium (fruits and vegetables), high protein (meats, fish, legumes, nuts), and high phosphorus (protein, low-fat dairy products) content for those with advanced CKD	Frequently monitor potassium, phosphorus, calcium, magnesium. If high normal or elevated: do not start DASH, discontinue DASH
Chronic heart failure	None	In addition to starting the DASH diet, restrict sodium intake (although research is lacking) per guideline recommendations for the general population
Diabetes mellitus type 2	Carbohydrate content may be higher than what is prescribed for some patients	Adopt a low-carbohydrate version of the DASH diet by substituting protein or monounsaturated fat for a portion of the carbohydrate content. Select foods with a low glycemic index
Chronic liver disease	<u>Compensated</u> : none <u>Decompensated</u> : high potassium content (fruits and vegetables) for patients with cirrhosis and moderate ascites	Compensated: DASH with no alterations. Also consider, sodium restriction (although research is lacking) per guideline recommendations for general population. Decompensated: DASH not recommended in this population
Diverticulitis	None (avoidance of seeds, corn, nuts, and berries is not currently recommended)	DASH with no alterations
Primary lactose intolerance	Lactose-containing products (low-fat dairy products)	Reduce intake of lactose-containing products and select lactose-reduced or lactose-free products. Supplement with oral digestive forms of lactase when consuming lactose-containing products
Celiac disease	Gluten-containing products (whole wheat) Lactose-containing products (low-fat dairy products)	Avoid gluten-containing grains, such as, wheat, rye, and barley. Select gluten-free foods, such as pure oats (limit to 50–60 g/day), brown rice, corn, and tapioca. Soybeans and potatoes can also be good sources of carbohydrates Temporarily limit lactose-containing products and select lactose-reduced or lactose-free products. See above recommendations for “primary lactose intolerance”
Use of renin-angiotensin-aldosterone system (RAAS) antagonists	High potassium content (fruits and vegetables)	Delay initiating DASH until the goal dose of RAAS inhibitor is achieved and normokalemia is confirmed

Therefore, clinicians will need to determine whether it is appropriate to initiate the DASH eating pattern prior to, simultaneously with, or after other therapies. However, timing of the initiation of the DASH diet in relation to other therapies has not been assessed. Therefore, one must draw on clinical experience and knowledge of how various patient factors (i.e., comorbid conditions, prescribed medications) may conflict with its dietary components.

For most patients, it is acceptable to initiate the DASH eating pattern simultaneously with other lifestyle interventions. As noted above, DASH combined with reduced sodium intake is more effective at lowering BP than either lifestyle intervention alone [41•]. In addition, lifestyle studies that combine DASH with weight loss suggest that the effects on BP are at least subadditive (i.e., greater than either intervention alone, but not completely additive) [60, 61•, 62, 63]. In addition to combining DASH with other lifestyle treatments, it is critically important to consider combining it with pharmacologic antihypertensive therapy: most patients with hypertension will require at least one BP medication. However, to our knowledge, only one trial has evaluated the combined effect of the DASH diet with a pharmacologic agent. The DASH-losartan trial showed a greater BP-lowering effect of the DASH diet plus the angiotensin receptor antagonist (ARB), losartan, than when either intervention was used alone [41•]. Evidence concerning the effect of DASH combined with other classes of antihypertensive agents, with multiple antihypertensive agents simultaneously, or in more severe hypertension is entirely lacking. Nonetheless, given the consistent BP-lowering effect of DASH alone or in combination with ARB, recommending the DASH diet at the same time with other therapies is an acceptable and preferred strategy to lower BP.

There is one occasion when it may be prudent to delay initiation of the DASH eating pattern until after medical therapy is established. Patients in whom RAAS inhibitors is initiated may have an increased risk of developing hyperkalemia, especially if they also have DM, CKD, or CVD [64, 65•]. In these patients, the DASH diet should not be initiated until the goal dosing of RAAS inhibitors is achieved and normokalemia is confirmed (Table 1).

Conclusion

The DASH eating pattern, like other lifestyle interventions, is important for optimal management of elevated BP. Quite often behavioral changes are recommended as an afterthought to antihypertensive medications, when in fact, they should be regarded as a cornerstone of therapy. The DASH eating pattern, which is rich in fruits, vegetables, low-fat dairy products, whole grains, lean meats and fish, with reduced sugar sweetened desserts and beverages, effectively

lowers BP alone and in combination with other therapies. Although caution should be taken in patients with CKD, DM, CVD, or those prescribed RAAS inhibitors, the DASH eating plan can generally be adopted by most patient populations and started simultaneously with medication therapy.

Disclosure No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance

1. Yoon SS, Osthega Y, Louis T. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999–2008. *NCHS Data Brief*. 2010;48:1–8.
2. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. *Arch Intern Med*. 1993;153(5):598–615.
3. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. *Blood Pressure Lowering Treatment Trialists' Collaboration*. *Lancet*. 2000;356(9246):1955–64.
4. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. *DASH Collaborative Research Group*. *N Engl J Med*. 1997;336(16):1117–24.
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. *JAMA*. 2003;289(19):2560–72.
6. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. *J Hum Hypertens*. 2004;18(3):139–85.
7. Program CHE. 2010 Canadian hypertension education program recommendations. An annual update. *Can Fam Physician*. 2010;56(7):649–53.
8. Sacks FM, Rosner B, Kass EH. Blood pressure in vegetarians. *Am J Epidemiol*. 1974;100(5):390–8.
9. Wright A, Burstyn PG, Gibney MJ. Dietary fibre and blood pressure. *Br Med J*. 1979;2(6204):1541–3.
10. Obarzanek E, Velletri PA, Cutler JA. Dietary protein and blood pressure. *JAMA*. 1996;275(20):1598–603.
11. Kesteloot H, Joossens JV. Relationship of dietary sodium, potassium, calcium, and magnesium with blood pressure. *Belgian Interuniversity Research on Nutrition and Health. Hypertension*. 1988;12(6):594–9.
12. Joffres MR, Reed DM, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. *Am J Clin Nutr*. 1987;45(2):469–75.
13. Margetts BM, Beilin LJ, Vandongen R, Armstrong BK. A randomized controlled trial of the effect of dietary fibre on blood pressure. *Clin Sci (Lond)*. 1987;72(3):343–50.
14. Swain JF, Rouse IL, Curley CB, Sacks FM. Comparison of the effects of oat bran and low-fiber wheat on serum lipoprotein levels and blood pressure. *N Engl J Med*. 1990;322(3):147–52.

15. Whelton PK, Appel L, Charleston J, Dalcin AT, Ewart C, Fried L, et al. The effects of nonpharmacologic interventions on blood pressure of persons with high normal levels. Results of the Trials of Hypertension Prevention, Phase I. *JAMA*. 1992;267(9):1213–20.
16. Wang Y, Wang QJ. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. *Arch Intern Med*. 2004;164(19):2126–34.
17. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med*. 2001;345(18):1291–7.
18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002;360(9349):1903–13.
19. Cooper R, Rotimi C. Hypertension in blacks. *Am J Hypertens*. 1997;10(7 Pt 1):804–12.
20. • Moranne O, Froissart M, Rossert J, Gauci C, Boffa JJ, Haymann JP, et al. Timing of onset of CKD-related metabolic complications. *J Am Soc Nephrol*. 2009;20(1):164–71. *This study shows the onset of various CKD-related metabolic complications at different levels of GFR.*
21. Kidney Disease Outcomes Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. *Am J Kidney Dis*. 2004;43(5 Suppl 1):S1–290.
22. Kidney Disease Outcomes Quality Initiative. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. *Am J Kidney Dis*. 2000;35(6 Suppl 2):S1–140.
23. Levey AS, Greene T, Beck GJ, Caggiula AW, Kusek JW, Hunsicker LG, et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown? Modification of Diet in Renal Disease Study group. *J Am Soc Nephrol*. 1999;10(11):2426–39.
24. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med*. 1994;330(13):877–84.
25. Locatelli F, Alberti D, Graziani G, Bucciatti G, Redaelli B, Giangrande A. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. *Lancet*. 1991;337(8753):1299–304.
26. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO₄, Ca x PO₄ product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. *J Am Soc Nephrol*. 2001;12(10):2131–8.
27. • Levitan EB, Wolk A, Mittleman MA. Consistency with the DASH diet and incidence of heart failure. *Arch Intern Med*. 2009;169(9):851–7. *This large prospective, observational study shows that diets consistent with the DASH diet are associated with lower rates of heart failure in at risk adults.*
28. Levitan EB, Wolk A, Mittleman MA. Relation of consistency with the dietary approaches to stop hypertension diet and incidence of heart failure in men aged 45 to 79 years. *Am J Cardiol*. 2009;104(10):1416–20.
29. Lopes HF, Martin KL, Nashar K, Morrow JD, Goodfriend TL, Egan BM. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. *Hypertension*. 2003;41(3):422–30.
30. Lin PH, Allen JD, Li YJ, Yu M, Lien LF, Svetkey LP. Blood pressure-lowering mechanisms of the DASH dietary pattern. *J Nutr Metab*. 2012;2012:472396.
31. Haider AW, Larson MG, Franklin SS, Levy D. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the Framingham Heart Study. *Ann Intern Med*. 2003;138(1):10–6.
32. Akita S, Sacks FM, Svetkey LP, Conlin PR, Kimura G. Effects of the Dietary Approaches to Stop Hypertension (DASH) diet on the pressure-natriuresis relationship. *Hypertension*. 2003;42(1):8–13.
33. Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. *Circulation*. 2006;114(1):82–96.
34. Liu LC, Voors AA, van Veldhuisen DJ, van der Veer E, Belonje AM, Szymanski MK, et al. Vitamin D status and outcomes in heart failure patients. *Eur J Heart Fail*. 2011;13(6):619–25.
35. Gotsman I, Shauer A, Zwas DR, Hellman Y, Keren A, Lotan C, Admon D. Vitamin D deficiency is a predictor of reduced survival in patients with heart failure; vitamin D supplementation improves outcome. *Eur J Hear Fail*. 2012;14(4):357–66.
36. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. *Arch Intern Med*. 2008;168(12):1340–9.
37. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. *Am J Clin Nutr*. 2006;83(4):754–9.
38. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA, Givertz MM, et al. HFSA 2010 comprehensive heart failure practice guideline. *J Card Fail*. 2010;16(6):e1–194.
39. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. *J Am Coll Cardiol*. 2009;53(15):e1–90.
40. Dunn SP, Bleske B, Dorsch M, Macaulay T, Van Tassel B, Vardeny O. Nutrition and heart failure: impact of drug therapies and management strategies. *Nutr Clin Pract*. 2009;24(1):60–75.
41. • Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. *N Engl J Med*. 2001;344(1):3–10. *This is a multi-center, randomized, controlled feeding study shows that the DASH diet plus sodium reduction reduces blood pressure greater than either intervention alone. This is the only study to make this comparison.*
42. American Diabetes Association. Standards of medical care in diabetes–2012. *Diabetes Care*. 2012;35 (Suppl 1):S11–63.
43. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, et al. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. *Diabetes Care*. 2008;31 Suppl 1:S61–78.
44. • Appel LJ, Sacks FM, Carey VJ, Obarzanek E, Swain JF, Miller ER, 3rd, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. *JAMA*. 2005;294(19):2455–64. *This randomized, crossover feeding study shows that a diet consistent with the DASH diet that partially substitutes carbohydrates with monounsaturated fat reduces blood pressure in adults with prehypertension and stage I hypertension. This is the only study to make this comparison.*
45. Franz M, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, et al. American Diabetes Association position statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *J Am Diet Assoc*. 2002;102(1):109–18.

46. The Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes. Recommendations for the nutritional management of patients with diabetes mellitus. *Eur J Clin Nutr.* 2000;54(4):353–5.
47. Brand-Miller J, Hayne S, Petocz P, Colagiuri S. Low-glycemic index diets in the management of diabetes: a meta-analysis of randomized controlled trials. *Diabetes Care.* 2003;26(8):2261–7.
48. Thomas D, Elliott EJ. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus. *Cochrane Database Syst Rev.* 2009;1:CD006296.
49. O'Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. *Hepatology.* 2010;51(1):307–28.
50. O'Brien A, Williams R. Nutrition in end-stage liver disease: principles and practice. *Gastroenterology.* 2008;134(6):1729–40.
51. Plauth M, Merli M, Kondrup J, Weimann A, Ferenci P, Muller MJ. ESPEN guidelines for nutrition in liver disease and transplantation. *Clin Nutr.* 1997;16(2):43–55.
52. Runyon BA. Management of adult patients with ascites due to cirrhosis: An update. *Hepatology.* 2009;49(6):2087–107.
53. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. *J Hepatol.* 2010;53(3):397–417.
54. Stollman NH, Raskin JB. Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. *Am J Gastroenterol.* 1999;94(11):3110–21.
55. Scrimshaw NS, Murray EB. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. *Am J Clin Nutr.* 1988;48(4 Suppl):1079–159.
56. Shaukat A, Levitt MD, Taylor BC, MacDonald R, Shamliyan TA, Kane RL, et al. Systematic review: effective management strategies for lactose intolerance. *Ann Intern Med.* 2010;152(12):797–803.
57. Benjamin RM. Dietary guidelines for Americans, 2010: the cornerstone of nutrition policy. *Public Health Rep.* 2011;126(3):310–1.
58. Barton SH, Kelly DG, Murray JA. Nutritional deficiencies in celiac disease. *Gastroenterol Clin North Am.* 2007;36(1):93–108. vi.
59. Thompson T. Gluten contamination of commercial oat products in the United States. *N Engl J Med.* 2004;351(19):2021–2.
60. Miller 3rd ER, Erlinger TP, Young DR, Jehn M, Charleston J, Rhodes D, et al. Results of the diet, exercise, and weight loss intervention trial (DEW-IT). *Hypertension.* 2002;40(5):612–8.
61. • Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. *Arch Intern Med.* 2010;170(2):126–35. *This randomized, controlled study of overweight and obese adults shows that the DASH diet plus weight loss causes greater reduction in blood pressure than the DASH diet alone.*
62. Appel LJ, Champagne CM, Harsha DW, Cooper LS, Obarzanek E, Elmer PJ, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. *JAMA.* 2003;289(16):2083–93.
63. Svetkey LP, Pollak KI, Yancy Jr WS, Dolor RJ, Batch BC, Samsa G, et al. Hypertension improvement project: randomized trial of quality improvement for physicians and lifestyle modification for patients. *Hypertension.* 2009;54(6):1226–33.
64. Ahuja TS, Freeman Jr D, Mahnken JD, Agraharkar M, Siddiqui M, Memon A. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. *Am J Nephrol.* 2000;20(4):268–72.
65. • Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. *Am J Cardiol.* 2012;109(10):1510–3. *This retrospective analysis of 15,803 patients with cardiovascular disease (defined as hypertension and heart failure) shows that chronic kidney disease, diabetes mellitus, and use of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists are significant predictors of hyperkalemia.*